Million Dollar Medical Cannabis Grant: Cansativa Closes Major Series A Funding

Pedro Gonçalo Ferreira
FrankfurtValley
3 min readJun 22, 2021

--

For the second time in less than a week, we wrote about the Medical Canabis market. This time the highlight is Cansativa GmbH (“Cansativa”), that has successfully completed the next important financing step, the Series A, after the seed financing and debt financing in the millions. As the industry leader in the field of medicinal cannabis, Cansativa already sells over 100 kilograms of cannabis flowers, over 100 different medicinal cannabis products as well as accessories and additional items to pharmacies throughout Germany every month. In 2021, the company will sell over two tons of cannabis flowers for the first time and thus achieve 8-digit sales across companies — a first in the industry. In the first quarter of the year, sales were already around 3 million euros. With its success story, the company attracts which holds the exclusive distribution rights for cannabis flowers from German cultivation, always attracts a lot of attention. The investor Greenfield Global Opportunities Fund has now also recognized the potential behind it and has joined the list of investors as a new name.

Series A funds are invested directly in company growth. Due to the high demand for the services, Cansativa is expanding its own storage capacities with several hundred additional pallet spaces and a new clean room manufacturing facility at the end of the year. With the help of the enlarged structures and optimized BtM contract logistics, the company should continue to grow as a “one-stop shop” and specialty retailer for medicinal cannabis.

“We are pleased about the new investor and the continued great trust in our business model and our brand. In the past four years we have been able to demonstrate the quality of our work and position ourselves as a pioneer in the medical cannabis industry. With the broadest market-encompassing portfolio and tailor-made solutions for the import, storage and distribution of narcotics, we have made a decisive contribution to the development of the industry and pave the way for a large number of companies to enter the German cannabis market. The completed financing round enables us to continue on this growth path and to continuously develop our company ”,

says Benedikt Sons, co-managing director and co-founder of Cansativa GmbH.

For the future, Cansativa GmbH plans to open up further business areas and expand its import and wholesale platform. The aim is to expand and improve services at all stages of the value chain, from import to storage and distribution.

“We see the cannabis market as a rapidly growing ecosystem, the design of which we want to shape with a view to the well-being of the patients — cooperative and accelerating. With our knowledge, tried and tested processes and infrastructures, we create access, remove obstacles and enable other companies to enter the market. We have big plans for the industry! Our import and logistics structures will continue to be decisive for the development of the industry in the future as the core component of the success to date “,

says Jakob Sons, co-managing director and co-founder of Cansativa GmbH.

Cansativa has established itself on the German medical cannabis market and is continuously working to improve the supply situation for medical cannabis.

--

--